RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life
Al-Samkari, H., Kasthuri, R. S., Iyer, V., Pishko, A. M., Decker, J. E., Whitehead, K. J., Conrad, M. B., Weiss, C., Parambil, J., Zumberg, M. S., Zhou, J. Y., Boyer, H., Sutton, V. R., Mazepa, M., Bradley, L., Clancy, M. S., Wisniewski, L., Carper, B., Catellier, D., ... Mccrae, K. R. (2023). PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life. Blood, 142(Supplement 2), LBA-3. https://doi.org/10.1182/blood-2023-191983